Conversations in Drug Development Trends
NOVEMBER 12, 2024
For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition.
Drug Target Review
SEPTEMBER 10, 2024
To achieve an aggressive timeline from DNA to investigational new drug (IND) application, drug developers have strengthened collaborations with contract development & manufacturing organisations (CDMOs) to expedite drug development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Drive: Drug Pricing
JUNE 9, 2025
Its new CEO has to figure out what’s next.
BioPharma Drive: Drug Pricing
JUNE 9, 2025
Most Popular Biotech funding plummets as Trump policies unnerve investors: Jefferies Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO FDA to use new review tool on Sarepta’s gene therapy work FDA meeting gives window into gene therapy field’s angst Library resources Playbook First-Void Urine Testing: A Simpler Option (..)
BioPharma Drive: Drug Pricing
JUNE 5, 2025
Bloomberg 23andMe’s DNA Data Gets Boosted $305 Million Bid in New Auction View all Events 17 JUN Webinar | 10:30 a.m. Its new CEO has to figure out what’s next.
Drug Target Review
MAY 27, 2025
I sequenced the complementary DNA (cDNA) encoding RAS GTPase Activating Protein, a protein known that regulates cell growth, differentiation and survival of cells; mutations in these proteins are linked to cancer. My proudest achievement is my leadership journey building legacy organisations, processes and tools in clinical operations.
Expert insights. Personalized for you.
Let's personalize your content